Patrizia Mulè
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patrizia Mulè has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Akihisa Fukuda
Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
1 shared publication - Alessandro D’aMbrosio
Laboratory of stem cells and cancer genomics, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123 Trento, Italy
1 shared publication - Alessandro Romanel
Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy
1 shared publication - Andrea Falqui
Department of Physics “Aldo Pontremoli”, University of Milan, via Celoria 16, 20133 Milan, Italy
1 shared publication Caterina Barbieri
Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, 20139 Milan, Italy
1 shared publication- Chiara Sartori
Unità Operativa Multizonale di Anatomia Patologica, APSS, 38122 Trento, Italy
1 shared publication
Latest Publications
- Open Access
- 15 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (11) , eadh4435
Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of Arid1a mutations
Oncogenic mutations accumulating in many chromatin-associated proteins have been identified in different tumor types. With a mutation rate from 10 to 57%, ARID1A has been widely considered a tumor suppressor gene. However, whether this role is mainly due to its transcriptional-related activities or its ability to preserve genome integrity is still a matter of intense debate. Here, we show that ARID1A is largely dispensable for preserving enhancer-dependent transcriptional regulation, being ARID1B sufficient and required to compensate for ARID1A loss. We provide in vivo evidence that ARID1A is mainly required to preserve genomic integrity in adult tissues. ARID1A loss primarily results in DNA damage accumulation, interferon type I response activation, and chronic inflammation leading to tumor formation. Our data suggest that in healthy tissues, the increased genomic instability that follows ARID1A mutations and the selective pressure imposed by the microenvironment might result in the emergence of aggressive, possibly immune-resistant, tumors.
- 15 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (11) , eadh4435
Open AccessIncreased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of Arid1a mutations
Oncogenic mutations accumulating in many chromatin-associated proteins have been identified in different tumor types. With a mutation rate from 10 to 57%, ARID1A has been widely considered a tumor suppressor gene. However, whether this role is mainly due to its transcriptional-related activities or its ability to preserve genome integrity is still a matter of intense debate. Here, we show that ARID1A is largely dispensable for preserving enhancer-dependent transcriptional regulation, being ARID1B sufficient and required to compensate for ARID1A loss. We provide in vivo evidence that ARID1A is mainly required to preserve genomic integrity in adult tissues. ARID1A loss primarily results in DNA damage accumulation, interferon type I response activation, and chronic inflammation leading to tumor formation. Our data suggest that in healthy tissues, the increased genomic instability that follows ARID1A mutations and the selective pressure imposed by the microenvironment might result in the emergence of aggressive, possibly immune-resistant, tumors.